ProCE Banner Activity

TRICOTEL: Phase II Study of Atezolizumab, Cobimetinib, and Vemurafenib in BRAFV600-Mutated Melanoma With CNS Metastases

Slideset Download
Conference Coverage
The combination of atezolizumab, cobimetinib, and vemurafenib showed promising intracranial activity in advanced BRAFV600-mutated melanoma with CNS metastases.

Released: June 15, 2022

Expiration: June 14, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab